Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry

In-vitro Diagnostics Market to grow by USD 35.77 billion | Evolving Opportunities with Abbott Laboratories & Danaher Corp | 17000+ Technavio Reports

PR Newswire ·  {{timeTz}}

NEW YORK, Nov. 29, 2021 /PRNewswire/ -- The "In-vitro Diagnostics Market - Competitive Analysis, Drivers, Challenges, and Five Force Analysis" report has been added to Technavio's offering. The In-vitro diagnostics market is set to grow by USD 35.77 billion, progressing at a CAGR of 7.95% from 2020 to 2025.

For more insights on the In-vitro Diagnostics Market - Download a free sample now!

Attractive Opportunities in In-vitro Diagnostics Market by Technology and Geography - Forecast and Analysis 2021-2025

35% of the market's growth will originate from North America. US, Mexico, and Canada are the key markets for in-vitro diagnostics in the region. The high demand for personalized medicine will facilitate the in-vitro diagnostics market growth in North America. The report offers an up-to-date analysis of the geographical composition of the market, competitive intelligence, and regional opportunities in store for vendors.

Market Dynamics

Factors such as the increasing geriatric population and chronic, and infectious diseases will be crucial in driving the growth of the market. However, the stringent regulatory bodies guiding in-vitro diagnostics manufacturers will restrict the market growth. The holistic analysis of the drivers will help in predicting end goals and refining marketing strategies to gain a competitive edge.

Company Profiles

The in-vitro diagnostics market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market. The in-vitro diagnostics market report includes information on the product launches, sustainability, and prospects of leading vendors including Abbott Laboratories, Danaher Corp., DiaSorin SpA, F. Hoffmann La Roche Ltd., Ortho Clinical Diagnostics Inc., QIAGEN NV, Quest Diagnostics Inc., Siemens AG, Sysmex Corp., and Thermo Fisher Scientific Inc.

Few Companies with Key Offerings

  • Abbott Laboratories - The company offers analyzers namely Alinity h series, CELL DYN Sapphire, CELL DYN Ruby, CELL DYN Ruby, and others for in vitro diagnostics.
  • Danaher Corp. - The company offers in vitro diagnostics for drug monitoring and prostate cancer detection.
  • DiaSorin SpA - The company offers in vitro diagnostics for infectious diseases, bone and mineral, hypertension, and serum proteins.

Competitive Analysis

The report includes the competitive analysis, a proprietary tool to analyze and evaluate the position of companies based on their industry position score and market performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Market Segmentation

  • By Technology, the market is classified into immunochemistry, molecular diagnostics, tissue diagnostics, hematology, and others. The in-vitro diagnostics market share growth by the immunochemistry segment has been significant
  • By Geography, the market is classified as North America, Europe, Asia, and ROW. North America will have the largest share of the market.

Related Reports -
Exosome Research Products Market -The exosome research products market share should rise by USD 163.33 million from 2021 to 2025 at a CAGR of 14.38%. Download a free sample now!

Radiation Dose Management Solution Market -The radiation dose management solution market share is expected to increase by USD 166.06 million from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 11.96%. Download a free sample now!

In-vitro Diagnostics Market Scope

Report Coverage

Details

Page number

120

Base year

2020

Forecast period

2021-2025

Growth momentum & CAGR

Accelerate at a CAGR of 7.95%

Market growth 2021-2025

USD 35.77 billion

Market structure

Fragmented

YoY growth (%)

6.23

Regional analysis

North America, Europe, Asia, and ROW

Performing market contribution

North America at 35%

Key consumer countries

US, Canada, Mexico, Germany, UK, France, China, Japan, and India

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

Abbott Laboratories, Danaher Corp., DiaSorin SpA, F. Hoffmann La Roche Ltd., Ortho Clinical Diagnostics Inc., QIAGEN NV, Quest Diagnostics Inc., Siemens AG, Sysmex Corp., and Thermo Fisher Scientific Inc.

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]Website: www.technavio.com/

SOURCE Technavio

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.